stoxline Quote Chart Rank Option Currency Glossary
  
ImmunoCellular Therapeutics, Ltd. (IMUC)
0.221  -0.035 (-13.65%)    03-18 10:17
Open: 0.2201
High: 0.24
Volume: 2,195
  
Pre. Close: 0.25593
Low: 0.2201
Market Cap: 25(M)
Technical analysis
2024-03-18 4:45:54 PM
Short term     
Mid term     
Targets 6-month :  13.12 1-year :  15.33
Resists First :  11.23 Second :  13.12
Pivot price 11.09
Supports First :  11.03 Second :  10.9
MAs MA(5) :  11.15 MA(20) :  11.08
MA(100) :  10.75 MA(250) :  10.6
MACD MACD :  0 Signal :  0
%K %D K(14,3) :  72.7 D(3) :  70.7
RSI RSI(14): 56.3
52-week High :  11.3 Low :  9.18
Price, MAs and Bollinger Bands

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ MUC ] has closed below upper band by 25.7%. Bollinger Bands are 35.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 11.23 - 11.27 11.27 - 11.32
Low: 11.03 - 11.08 11.08 - 11.13
Close: 11.1 - 11.18 11.18 - 11.25
Company Description

Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.

Headline News

Sat, 16 Mar 2024
Head to Head Contrast: Novartis (NYSE:NVS) vs. EOM Pharmaceuticals (OTCMKTS:IMUC) - Defense World

Thu, 07 Mar 2024
EOM Pharmaceuticals (OTCMKTS:IMUC) Trading 14.3% Higher - American Banking and Market News - American Banking News

Thu, 07 Mar 2024
EOM Pharmaceuticals (OTCMKTS:IMUC) Stock Price Up 14.3% - Defense World

Thu, 10 Nov 2022
EOM PHARMACEUTICAL HOLDINGS, INC. ANNOUNCES NAME CHANGE FROM IMMUNOCELLULAR ... - BioSpace

Thu, 02 Dec 2021
EOM Pharmaceuticals, Inc. And Immunocellular Therapeutics, Ltd. Announce Entry Into And Close Of Definitive Merger ... - PR Newswire

Tue, 11 Apr 2017
For These Small-Cap Biotech CEOs, Stock Promotion, Not Drug Development, Was Priority No. 1 - TheStreet

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Neutral
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Outperform
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Outperform
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Outperform
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Neutral
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Underperform
Stock Basics & Statistics
Exchange:
PNK
Sector:
Healthcare
Industry:
Biotechnology
Shares Out 95 (M)
Shares Float 0 (M)
Held by Insiders 0 (%)
Held by Institutions 31.7 (%)
Shares Short 137 (K)
Shares Short P.Month 191 (K)
Stock Financials
EPS -0.26
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 12.68
Profit Margin -39.2 %
Operating Margin 86.5 %
Return on Assets (ttm) 2 %
Return on Equity (ttm) -2.4 %
Qtrly Rev. Growth 21.3 %
Gross Profit (p.s.) 0
Sales Per Share 0.79
EBITDA (p.s.) 0
Qtrly Earnings Growth 0 %
Operating Cash Flow 327 (M)
Levered Free Cash Flow 24 (M)
Stock Valuations
PE Ratio -43.01
PEG Ratio 0
Price to Book value 0.88
Price to Sales 13.97
Price to Cash Flow 3.26
Stock Dividends
Dividend 0.05
Forward Dividend 0
Dividend Yield 0.4%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android